Mucosal and circulating immunity against SARS-CoV-2 among healthcare professionals working with COVID-19 patients

Completed

• Conditions: COVID-19; SARS-CoV-2; 10047438

• Registration Number: NL-OMON49305
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 350

Inclusion Criteria

healthcare professionals working or having worked (in a department) with
COVID-19 patients within the LUMC

Exclusion Criteria

below 18 years old

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study outcome will be the prevalence of mucosal IgA and circulating<br /><br>IgA and IgG SARS-CoV-2 antibodies.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary study outcomes will be the evolution of the titers of these mucosal<br /><br>IgA and circulating IgA and IgG SARS-CoV-2 antibodies over time and the<br /><br>relation of their presence to symptom severity. Furthermore, the potential<br /><br>relation between the presence of mucosal IgA SARS-CoV-2 antibodies and the<br /><br>presence of PCR-detectable coronaviruses other than SARS-CoV-2 in saliva will<br /><br>be assessed. </p><br>